- Location
Xalkori
"-
Pfizer Has Secured Regular Approval From The Us Food and Drug Administration (FDA)
Nov 25, 2013Pfizer has secured regular approval from the US Food and Drug Administration (FDA) for its Xalkori (crizotinib) capsules to treat patients with metastatic ALK-positive non-small cell lung cancer (NSCLC). The approval was based on ...
-
European Commission Granted Conditional Marketing Authorization for Pfizer's Xalkori
Dec 6, 2012The European Commission has granted conditional marketing authorization for Pfizer’s Xalkori (crizotinib) to treat anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) in the European Union (EU). ...
Tags: Xalkori, crizotinib, anaplastic lymphoma kinase, ALK
-
Cytocell Unveiled a ROS1 Breakapart FISH Probe Test for Non-Small-Cell Lung Cancer
Dec 5, 2012Cytocell, a developer of fluorescence in situ hybridization (FISH) probes for use in cancer analysis, has unveiled a ROS1 Breakapart FISH probe test for non-small-cell lung cancer (NSCLC). The molecular cytogenetic test, which utilizes ...
-
Abbott Expands CE-IVD Product Labeling for Its Vysis Alk Break Apart Fish Probe Kit
Dec 4, 2012Abbott will expand the current CE-IVD product labeling for its Vysis ALK Break Apart FISH Probe Kit to allow the test to be marketed in the European Union as a companion diagnostic. The test uses Abbott's proprietary fluorescence in situ ...
Tags: Abbott, anaplastic lymphoma kinase, ALK, FISH technology
-
Pfizer Canada Has Announced The Availability of Xalkori for Patients
Nov 29, 2012Pfizer Canada has announced the availability of Xalkori (crizotinib) for patients with anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC) in Canada. A validated ALK assay should be used to ...
Tags: ALK, ALK-positive lung cancer, Pfizer Canada
